Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IVVD
IVVD | US
1.71
USD0
0%
IVVD | US
About IVVD
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
1.71
Open
1.73
High
1.73
Low
1.65
Invivyd Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease as well as developing monoclonal antibody candidates including VYD222 and VYD224 which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd Inc. has a collaboration agreement with Adimab LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics Inc. and changed its name to Invivyd Inc. in September 2022. Invivyd Inc. was incorporated in 2020 and is headquartered in Waltham Massachusetts.
View LessIVVD | US
Risk
144.7
Sharpe
1.52
Luna's Score
60/100
Recommendation
Hold
Luna says (IVVD | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
171.4%1 month
144.7%3 months
102.7%6 months
116.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.82
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
0.78
Ent. to rev.
3.04
PEG
-
Other Fundamentals
EBITDA
-210.66M
MarketCap
204.25M
MarketCap(USD)
204.25M
Div. yield
-
Op. margin
-2.18K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-96.56
Short ratio
14.07
Short perc.
8.65
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.58
Range1M
0.63
Range3M
1.47
Volumes: Market Activity
Rel. volume
0.32
Price X volume
2.15M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.78 | - | Expensive |
| Ent. to Revenue | 3.04 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.82 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 102.71 | - | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 204.25M | - | Emerging |
